Product Description
Mechanisms of Action: CD4 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biotest AG
Company Location: Europe
Company Founding Year: 1946
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Arthritis, Rheumatoid|Psoriasis|Environmental Hypersensitivity|Asthma, Allergic|Inflammation|Dust mite Hypersensitivity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2020-000585-41 |
Tregulaire | P2 |
Completed |
Asthma, Allergic|Environmental Hypersensitivity|Dust mite Hypersensitivity |
2022-01-12 |
2025-07-09 |
Treatments |
|
NCT04673591 |
Tregulaire | P2 |
Completed |
Dust mite Hypersensitivity|Asthma, Allergic|Environmental Hypersensitivity|Inflammation |
2022-01-12 |
43% |
2022-02-10 |
Primary Endpoints |
2013-000114-38 |
T cell REgulating Arthritis Trial 2b (TREAT 2b) | P2 |
Terminated |
Arthritis, Rheumatoid |
2016-11-29 |
2022-03-13 |
Treatments |
|
NCT01999192 |
986 | P2 |
Terminated |
Arthritis, Rheumatoid |
2015-07-01 |
2019-03-20 |
||
2010-018485-24 |
BT061 plus MTX in RA | P2 |
Completed |
Arthritis, Rheumatoid |
2013-08-05 |
2022-03-13 |
Treatments |
|
NCT01481493 |
NCT01481493 | P2 |
Completed |
Arthritis, Rheumatoid |
2013-08-01 |
2019-03-19 |
Treatments |
|
NCT01072383 |
NCT01072383 | P2 |
Completed |
Psoriasis |
2011-06-01 |
2019-03-19 |
Treatments |
|
2008-007458-37 |
2008-007458-37 | P2 |
Completed |
Psoriasis |
2011-05-23 |
2025-07-09 |
Treatments |
|
2008-001241-26 |
n.a. | P2 |
Completed |
Arthritis, Rheumatoid |
2011-04-01 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|